The MoCRA Countdown: Is Your Cosmetic Brand Audit-Ready for 2026?
The Modernization of Cosmetics Regulation Act (MoCRA) has fundamentally changed what it means to manufacture cosmetics in the United States. For the first time since 1938, the FDA has real enforcement power over the cosmetics industry — and the compliance deadlines are no longer theoretical.
If you are a cosmetic manufacturer, contract manufacturer, or private label brand owner, the question is no longer whether you need to comply. The question is whether you can prove compliance when the FDA comes knocking.
What MoCRA Actually Requires
Many cosmetic manufacturers are still operating under the assumption that cosmetics regulation is "light touch." That era is over. Here is what MoCRA now mandates:
Mandatory Facility Registration
Every facility that manufactures or processes cosmetics for the U.S. market must register with the FDA. This is not the old voluntary cosmetic registration program — this is mandatory, and failure to register can result in enforcement action.
If your facility manufactures both cosmetics and dietary supplements, you need dual registration. Your supplement registration under 21 CFR Part 111 does not cover your cosmetic operations.
Product Listing
Every cosmetic product marketed in the U.S. must be listed with the FDA, including:
- Complete ingredient lists
- Product labeling details
- Manufacturing facility information
- Responsible Person contact information
This creates a searchable database that the FDA can audit at any time. If your product is on the market but not in the database, you are already out of compliance.
The "Responsible Person" Requirement
MoCRA introduces the concept of a Responsible Person — the individual or entity legally accountable for the safety and labeling of each cosmetic product. For most brands, this is the manufacturer or the brand owner who puts their name on the label.
The Responsible Person must:
- Maintain records demonstrating product safety
- Report serious adverse events to the FDA within 15 business days
- Ensure accurate and compliant labeling
- Respond to FDA requests for safety substantiation
This is where many small brands get caught off guard. If someone has a serious reaction to your product and you cannot provide safety documentation to the FDA within 15 days, your business is at immediate risk.
Good Manufacturing Practices (GMP)
MoCRA mandates that cosmetics be manufactured in accordance with GMP standards. While the FDA is still finalizing specific cosmetic GMP guidance, the expectation is clear: you need documented procedures, controlled processes, and evidence that you follow them.
Manufacturers who already follow supplement GMPs under 21 CFR Part 111 have a significant head start. The core principles — personnel training, facility maintenance, equipment calibration, batch documentation, and quality testing — apply directly.
The 15-Day Adverse Event Clock
Of all the MoCRA requirements, the adverse event reporting timeline creates the most operational pressure.
When a serious adverse event is reported:
- Day 0 — You receive a report of a serious health-related reaction to your product
- Days 1-5 — You need to identify which product, which batch, which ingredients, and which manufacturing records are involved
- Days 5-10 — You need to compile safety substantiation, batch records, ingredient traceability, and any relevant testing data
- Days 10-15 — You need to submit your report to the FDA with all supporting documentation
If your records are scattered across spreadsheets, paper binders, email chains, and personal hard drives, assembling this documentation within 15 days is a crisis. If your records are organized in a single system with proper batch tracking and audit trails, it is a process.
What the FDA expects you to have ready:
- Batch records for the specific product lot in question
- Ingredient traceability — which raw material lots went into that batch, and where they came from
- Manufacturing records — who made it, when, under what conditions
- Quality testing results — any in-process or finished product testing
- Complaint history — any prior complaints about the same product or batch
The "Infrastructure of Proof"
The gap between "we follow good practices" and "we can prove we follow good practices" is where most cosmetic manufacturers fail during an FDA interaction. Having good intentions is not compliance. Having documented evidence is.
This is what we call the Infrastructure of Proof — the systems and records that transform your daily manufacturing activities into auditable, defensible documentation.
What an infrastructure of proof looks like:
Audit trails that cannot be edited — Every change to a formulation, batch record, or quality decision is logged with who made the change, when they made it, and what the previous value was. You cannot go back and "clean up" records before an audit.
Electronic signatures tied to individuals — When your quality manager releases a batch or your Responsible Person approves a formulation change, that decision is recorded with a cryptographic signature that cannot be forged or reassigned.
Lot-level ingredient traceability — For any finished product batch, you can trace backward to every ingredient lot used, including supplier information, certificates of analysis, and receiving dates. For any ingredient lot, you can trace forward to every finished product batch that contains it.
Timestamped, immutable records — Every action is recorded in real time as work happens. Records are not filled in after the fact from memory or reconstructed for an audit.
How Batch Buddy Provides the Infrastructure
Batch Buddy was designed around FDA 21 CFR Part 11 compliance — the regulation that governs electronic records and electronic signatures. For cosmetic manufacturers facing MoCRA requirements, this means the compliance infrastructure is already built:
Immutable audit trails — Every change to any record is automatically logged with a timestamp, user identity, and before/after values. Audit entries cannot be deleted or modified, meeting the FDA's requirement for tamper-evident record-keeping.
Electronic signatures — Batch releases, QC approvals, and formulation changes are signed electronically by the responsible individual. Each signature is cryptographically unique, time-stamped, and permanently linked to the specific record.
Complete batch documentation — Electronic Batch Records (EBR) capture the full production story: ingredients used (with specific lot numbers), quantities, process steps, operator sign-offs, and any deviations. When the FDA asks "show me the batch record for lot XYZ," you generate a PDF in seconds.
Ingredient traceability — When you receive raw materials, the system captures batch numbers, supplier information, COA data, and receiving dates. When you run production, the system automatically records which ingredient lots were consumed. The full traceability chain — from supplier to finished product to customer — is maintained without additional manual effort.
Record retention — All records are stored securely with soft deletion. Nothing is permanently erased, meeting the FDA's expectation that records be available for the required retention period.
Your MoCRA Readiness Checklist
Use this checklist to evaluate your current compliance posture:
Facility and Registration
- [ ] Facility registered with the FDA under MoCRA
- [ ] All marketed products listed in the FDA database
- [ ] Responsible Person identified and documented for each product
Record-Keeping
- [ ] Batch records maintained for every production run
- [ ] Ingredient traceability from supplier to finished product
- [ ] Audit trail capturing all changes to formulations and records
- [ ] Electronic signatures for batch releases and quality decisions
Adverse Event Readiness
- [ ] Process documented for receiving and evaluating complaints
- [ ] Ability to identify affected batches within hours, not days
- [ ] Safety substantiation documentation accessible and organized
- [ ] 15-day reporting timeline achievable with current systems
Good Manufacturing Practices
- [ ] Written SOPs for all manufacturing processes
- [ ] Personnel training records maintained
- [ ] Equipment calibration and maintenance logs current
- [ ] In-process and finished product testing documented
- [ ] Deviation and corrective action procedures in place
Labeling Compliance
- [ ] Ingredient lists accurate and complete
- [ ] INCI naming conventions followed
- [ ] Allergen disclosures current with MoCRA requirements
- [ ] Label claims substantiated with supporting data
The Bottom Line
MoCRA compliance is not a one-time project — it is an ongoing operational requirement. The manufacturers who will navigate this transition successfully are the ones who build compliance into their daily workflows rather than treating it as a separate activity that gets attention only when an audit is imminent.
The cost of building the right infrastructure now is a fraction of the cost of responding to an FDA enforcement action later. And unlike a paper-based system that degrades over time as staff turn over and binders get misplaced, a digital compliance infrastructure maintains its integrity automatically.
The countdown is not to a single deadline. It is to a permanent shift in how the cosmetics industry operates. The question is whether your operation is built for this new reality.